<?xml version="1.0" encoding="UTF-8"?>
<p id="Par38">Chloroquine phosphate (CQ) has been used effectively to manage CHIKV arthritis [
 <xref ref-type="bibr" rid="CR36">36</xref>]. In a previous study, the authors used hydroxychloroquine (HCQ) to treat patients with chronic CHIK arthritis, with 79% of patients showing a good response [
 <xref ref-type="bibr" rid="CR28">28</xref>]. A 24-week, two-arm parallel efficacy trial comparing CQ and meloxicam did not show any significant difference in efficacy between the two drugs [
 <xref ref-type="bibr" rid="CR37">37</xref>]. A very recent randomized controlled trial compared combinations of disease-modifying anti-rheumatic drugs (DMARDs), namely, methotrexate, sulfasalazine, and HCQ with HCQ monotherapy, and found better efficacy with DMARDs [
 <xref ref-type="bibr" rid="CR38">38</xref>]. Ganu et al. found good response with a combination of sulfasalazine and methotrexate compared to sulfasalazine alone in patients with chronic persistent CHIK arthritis not responding to NSAIDs and HCQ for 3 months [
 <xref ref-type="bibr" rid="CR39">39</xref>].
</p>
